AP NEWS

Global Post-Operative Pain Pipeline Review, H2 2018 - Therapeutic Assessment of 40 Companies - ResearchAndMarkets.com

September 26, 2018

DUBLIN--(BUSINESS WIRE)--Sep 26, 2018--The “Post-Operative Pain - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Post-Operative Pain - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Post-Operative Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The Post-Operative Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 2, 8, 18, 8, 3, 19, 3 and 4 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 1 and 1 molecules, respectively.

Post-Operative Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Post-Operative Pain - Overview Post-Operative Pain - Therapeutics Development Post-Operative Pain - Therapeutics Assessment Post-Operative Pain - Companies Involved in Therapeutics Development Post-Operative Pain - Drug Profiles Post-Operative Pain - Dormant Projects Post-Operative Pain - Discontinued Products Post-Operative Pain - Product Development Milestones Appendix Abide Therapeutics Inc AcelRx Pharmaceuticals Inc Adynxx Inc AngioChem Inc Aoxing Pharmaceutical Company Inc Apsen Farmaceutica SA Cadila Healthcare Ltd Camurus AB Cara Therapeutics Inc Center Laboratories Inc CerSci Therapeutics Inc Colby Pharmaceutical Co Dompe Farmaceutici SpA Eupraxia Pharmaceuticals Inc EyeGate Pharmaceuticals Inc Fujimoto Pharmaceutical Corp GW Pharmaceuticals Plc Heron Therapeutics Inc Immupharma Plc Innocoll AG Lipocure Ltd Liquidia Technologies Inc Lumosa Therapeutics Co Ltd Medtronic Plc Mundipharma International Ltd Neumentum Inc Novartis AG Ocular Therapeutix Inc Pacira Pharmaceuticals Inc PainReform Ltd Pharmaleads SA PhytoHealth Corp Trevena Inc Virpax Pharmaceuticals Inc Xigen SA

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/mp89t3/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180926006011/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Analgesics

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/26/2018 04:23 PM/DISC: 09/26/2018 04:22 PM

http://www.businesswire.com/news/home/20180926006011/en

AP RADIO
Update hourly